{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-081484","form_type":"8-K","ticker":null,"cik":"0001567892","company_name":"Keenova Therapeutics plc","filed_at":"2023-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.365424+00:00","generated_at":"2026-06-13T07:40:17.572713+00:00","sec_items":["1.01","8.01","2.03","2.04","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Mallinckrodt enters forbearance on missed interest; $200M opioid payment extended to Aug 15","bullets":["Missed June 15 interest payments on 11.5% 2028 First Lien Notes and 10% 2029 Second Lien Notes triggered defaults.","Forbearance agreements signed July 16 with >75% of first-lien and majority of second-lien holders, plus lenders, through Aug 15.","Borrowed $100M under ABL credit facility on July 13; ABL margin increased 1% and availability capped at $100M.","Opioid Trust extended $200M deferred payment from July 21 to Aug 15; $450M already paid in June 2022.","Board has not determined ultimate path, including possible filing under U.S. Bankruptcy Code."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-081484","json":"https://secwatch.observer/filing/0001104659-23-081484.json","markdown":"https://secwatch.observer/filing/0001104659-23-081484.md","text":"https://secwatch.observer/filing/0001104659-23-081484.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567892/000110465923081484/0001104659-23-081484-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567892/000110465923081484/tm2321318d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T07:40:17.572713+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"835edacd780092d7f9e2cee53eb62292b3fa2747","claim":"Keenova Therapeutics plc incurred credit facility of $100.0 million.","evidence_excerpt":"On July 13, 2023, ST US AR Finance LLC borrowed $100.0 million under the ABL Credit Agreement in order to maximize cash on hand.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000110465923081484/0001104659-23-081484-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"$100.0 million"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}